WO1991005537A1 - Procede d'acceleration de la cicatrisation de plaies et d'ulceres, et de traitement de maladie periodontique - Google Patents
Procede d'acceleration de la cicatrisation de plaies et d'ulceres, et de traitement de maladie periodontique Download PDFInfo
- Publication number
- WO1991005537A1 WO1991005537A1 PCT/US1990/005716 US9005716W WO9105537A1 WO 1991005537 A1 WO1991005537 A1 WO 1991005537A1 US 9005716 W US9005716 W US 9005716W WO 9105537 A1 WO9105537 A1 WO 9105537A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bond
- hydrogen
- proviso
- vitamin
- double bond
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 22
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 20
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 10
- 206010052428 Wound Diseases 0.000 title claims description 34
- 230000035876 healing Effects 0.000 title abstract description 25
- 208000027418 Wounds and injury Diseases 0.000 title description 33
- -1 vitamin D compound Chemical class 0.000 claims abstract description 50
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 46
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 46
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 46
- 239000011710 vitamin D Substances 0.000 claims abstract description 46
- 229940046008 vitamin d Drugs 0.000 claims abstract description 46
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 230000029663 wound healing Effects 0.000 claims abstract description 13
- 230000002183 duodenal effect Effects 0.000 claims abstract description 7
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 230000002496 gastric effect Effects 0.000 claims abstract description 7
- 230000036573 scar formation Effects 0.000 claims abstract description 7
- 206010064996 Ulcerative keratitis Diseases 0.000 claims abstract description 6
- 201000007717 corneal ulcer Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims abstract description 5
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 96
- 239000001257 hydrogen Substances 0.000 claims description 80
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 229910052731 fluorine Inorganic materials 0.000 claims description 32
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000003700 epoxy group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 208000034693 Laceration Diseases 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000005640 glucopyranosyl group Chemical group 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 7
- 208000008960 Diabetic foot Diseases 0.000 claims description 4
- 208000035874 Excoriation Diseases 0.000 claims description 4
- GRHZLQBPAJAHDM-SPRQWYLLSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound CC1=CC=CC(C)=C1OCC(=O)N[C@H]([C@@H](O)C[C@H](CC=1C=CC=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 GRHZLQBPAJAHDM-SPRQWYLLSA-N 0.000 claims description 4
- 238000005299 abrasion Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 231100000241 scar Toxicity 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 11
- 229960005084 calcitriol Drugs 0.000 description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 description 10
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 210000001626 skin fibroblast Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- LRNVEDCUBISUTC-OWRPZGOZSA-N 24,24-difluoro-25-hydroxyvitamin D3 Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@@H](CCC(F)(F)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C LRNVEDCUBISUTC-OWRPZGOZSA-N 0.000 description 1
- QYSXJUFSXHHAJI-FVUVGDFOSA-N 5,6-trans-vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-FVUVGDFOSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010051714 Calciphylaxis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000030402 vitamin D-dependent rickets Diseases 0.000 description 1
- 150000003703 vitamin D2 derivatives Chemical class 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention is in the field of medicinal chemistry.
- the present invention relates to novel methods for
- Skin Human skin is a complex integration of different types of cells and tissues which form an organ. Skin is also the primary seat of the sense of touch and creates a covering for the protection of th ⁇ deeper tissues. The skin also plays an important role in the regulation of body temperature and is also an excretory and absorbing organ. Skin consists primarily of a layer of vascular tissue and an external covering of epithelium known as the epidermis. On the surface layer are the sensitive papillae and alongside or imbedded beneath it are certain specialized organs, specifically the sweat glands, hair follicles, and sebaceous glands.
- wounds which are caused by physical means, result in a disruption of the normal continuity of the structures of the skin. Examples of wounds include cuts, punctures, lacerations, etc.
- stomach lining is also composed of internal epithelium (endotheliu ).
- Gastric ulcers are a result of damage or erosion of the stomach lining. Gastric ulcers occur along the lesser curvature of the stomach where the pyloric glands border the oxyntic gland. They are usually 1 to 2.5 cm in diameter; however, they can vary from a few mm to several cm. Ulcers are usually round, oval or elliptical, with sharply defined margins. The surrounding mucosa is often hyperemic and edematous. Ulcers penetrate into the submucosa or muscular layer.
- a thin layer of gray or white exudate usually covers the base of the ulcers; this layer is composed of fibrinoid, granulation and fibrous tissue layers.
- fibrous tissue in the base contracts the ulcer and may distort the surrounding tissue.
- healing continues as granulation tissue fills the base and epithelium from the ulcer edges cover its surface.
- the mechanism of epithelial wound healing is a complex process involving ultrastructural changes of epithelial cells. These changes allow for detachment from neighboring cells, migration and subsequent reattachment.
- the migration of epithelial cells has been found to depend on a suitable matrix composed of fibrin, fibronectin or basement membrane which traverse the wound. Clark, R., J. Am. Acid Derm.. 13:701-718 (1985); Zitelli, J., Adv. Dermatol . 2:243-268 (1987).
- the process involves clotting and formation of a crust or scab to seal the wound; an acute inflammatory reaction; reepithelialization of the surface and fibrous bridging due to fibrin followed by complete sealing of the wound by an epithelial covering. Thereafter, hair follicles, sebaceous glands and sweat glands may subsequently regenerate.
- the process of second intention healing requires the removal of necrotic debris. The gap in the wound then fills in with fibrous materials.
- carbenoxolene is used to treat gastric ulcers.
- Carbenoxolene is a hydrolytic product of glycyrrhizic acid (derivativ of licorice); it has been shown to increase the rate of gastric ulce healing. Braunwald, E., Harrison's Principles of Internal Medicin 11th ed. p. 1247. It appears to increase the life span of gastri mucosal epithelial cells and increase the secretion and viscosity o gastric mucus.
- carbenoxolene has aldosterone-like effects, therefore it tends to increase the rate at which the body retain sodium and water. These effects may be blocked by aldosterone antagonists, however the antagonists obliterate the healing effects o the carbenoxolene. There is a need for therapies which can promot healing without the negative side effects.
- the skin may be a targe tissue for 1,25-(0H) -D3 (Stumpf, W.E. et al.. Science. 201:1188-119 (1979)).
- Cells isolated from the skin of rats, mice, and humans, an from cultured human skin fibroblasts and keratinocytes contain a hig affinity (1.0 x 10 "10 M) low capacity receptor-like protein for 1,25 dihydroxyvitamin D3 (Franceschi, et al .. Arch. Biochem. Biophys. 210: 1-13 (1979); Simpson, R. U. et al., P.N.A.S. (USA). 77: 582 (1980); Colston, K. et al..
- Holick, U.S. Patent No. 4,410,545 discloses vitamin D glycosides and their use in the regulation of calcium metabolism and phosphorous homeostasis.
- Holick, U.S. Patent No. 4,521,410 discloses water-soluble glycosyl orthoesters of vitamin D and their use in the regulation of calcium metabolism and phosphorous homeostasis.
- Calciphylaxis is a hypersensitivity reaction resulting from the administration of or endogenous production of a sensitizing calcifier in combination with a challenger.
- Sensitizing calcifiers include, inter alia, vitamins D2 and D3.
- Dikstein U.S. Patent No. 4,610,478, and European Patent Application No. 0 129003 (1984), discloses compositions containing 1- alpha-hydroxycholecalciferol or 1-alpha,25-dihydroxycholecalciferol for the topical treatment of skin disorders, such as dermatitis, psoriasis, eczema, solar keratosis and certain stages of wound healing and alopecia.
- Dikstein also teaches that low dosages are required, from about 0.03 ⁇ g to 1.0 ⁇ g per gram of composition, to minimize the risk of undesired side effects and systemic effects.
- Dikstein does not teach that vitamin D compounds are useful for the treatment of wounds caused by lacerations, punctures or cuts.
- the invention relates to a method of enhancing the healing of wounds in a patient comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the Formula (I):
- Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
- U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
- Zl is F, H or X 1 ;
- Q a is CF 3 or CH2X 1 ;
- Q b is CF 3 or CH 3 ;
- R is a double bond or an epoxy group; wherein ⁇ l is selected from the group consisting of hydrogen and -OH; W is CH-CH3 or 0; and V is CH2 or 0; with the proviso that both W and V are not both 0; and
- the invention also relates to a method of enhancing the healing of wounds in a patient which comprises administering to said patient an effective amount of a vitamin D compound, wherein said vitamin D compound has the
- Y 2 is hydrogen, fluorine, methyl, ethyl or OR*;
- Z 2 is F, H or X 2 ;
- U is hydrogen, -OH or -0-(C -C4 alkyl)-0H;
- Q a is CF 3 or CH 2 X 2 ;
- Q b is CF 3 or CH3;
- R is a double bond or an epoxy group
- X 2 is selected from the group consisting of hydrogen
- R! is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R! is an orthoester glycoside moiety of the Formula (III):
- A represents a glucofuranosyl or glucopyranosyl ring
- R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
- R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, with the proviso that at least one of the R! is either a glycosidic residue or an orthoester glycoside moiety;
- W is CH-CH3 or 0
- V is CH 2 or 0; with the proviso that both W and V are not both 0;
- the invention also relates to a method of inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
- Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
- U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
- Z 1 is F, H or X 1 ;
- Q a is CF 3 or CH 2 X ;
- Q b is CF 3 or CH 3 ;
- R is a double bond or an epoxy group; wherein ⁇ is selected from the group consisting of hydrogen and -OH;
- W is CH-CH3 or 0; and with the proviso that both W and V are not both 0; and
- the invention also relates to a method for inhibiting scar formation in a patient arising from cuts, lacerations, puncture wounds and abrasions which comprises topically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
- Y 2 is hydrogen, fluorine, methyl, ethyl or OR 1 ;
- U is hydrogen, -OH or -0-(C2-C4 alkyl)-OH;
- Z 2 is F, H or X 2 ;
- Q a is CF 3 or CH 2 X 2 ;
- Q b is CF 3 or CH 3 ;
- R is a double bond or an epoxy group
- X 2 is selected from the group consisting of hydrogen, and
- R 1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R 1 is an orthoester glycoside moiety of the Formula (III):
- A represents a glucofuranosyl or glucopyranosyl ring
- R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
- R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
- W is CH-CH3 or 0
- V is CH2 or 0; with the proviso that both W and V are not both 0;
- the invention also relates to a method of treating gastric, duodenal, esophageal , decubitus, diabetic foot and genito-urinary ulcers in a patient which comprises administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (I):
- Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
- U is hydrogen, -OH or -0-(C2-C4 alkyl)-0H;
- Z 1 is F, H or X 1 ;
- Q a is CF 3 or CH2X 1 ;
- Q b is CF 3 or CH 3 ;
- R is a double bond or an epoxy group; wherein X 1 is selected from the group consisting of hydrogen and -OH;
- W is CH-CH3 or 0
- V is CH2 or 0; with the proviso that both W and V are not both 0;
- the invention also relates to a method for treating gastric, duodenal, esophageal, decubitus, diabetic foot, genito-urinary ulcers and ulcerative keratitis in a patient which comprises topically or ophthalmically administering to said patient a pharmaceutical composition comprising an effective amount of a vitamin D compound and a pharmaceutically acceptable carrier, wherein said vitamin D compound has the Formula (II):
- Y 2 is hydrogen, fluorine, methyl, ethyl or ORl
- U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
- Z 2 is F, H or X 2 ;
- Q a is CF 3 or CH 2 X 2 ;
- Q b is CF 3 or CH 3 ;
- R is a double bond or an epoxy group
- X 2 is selected from the group consisting of hydrogen, and
- R 1 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R 1 is an orthoester glycoside moiety of the Formula (III):
- A represents a glucofuranosyl or glucopyranosyl ring
- R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower 1-C4 alkyl, C1-C4 alkoxy; or naphthyl; and
- R3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
- W is CH-CH3 or 0
- V is CH 2 or 0; with the proviso that both W and V are not both 0;
- Figure 1 depicts a graph showing the effect of vehicle and 5 ⁇ g, 10 ⁇ g, 27 ⁇ g and 54 ⁇ g of 1,25-dihydroxyvitamin D per gram of oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 6 in rats with experimental wounds.
- Figure 2 depicts a graph showing the effect of vehicle and 27 ⁇ g 1,25-dihydroxyvitamin D3/gram oil on the percentage of wound healing on days 1, 2, 3, 4, 5 and 9 in rats with experimental wounds.
- the present invention provides for a method of healing wounds and inhibiting scar formation.
- Wounds to the external epithelium include cuts, punctures and lacerations, including corneal lacerations.
- Wounds of the internal epithelium include peptic ulcers, esophageal mucosa injury, oral mucosa injuries and periodontal disease.
- the invention also provides for the treatment of ulcers such as diabetic ulcers of the feet, decubitus ulcers (bed sores), genito-urinary ulcers, peptic ulcers and ulcerative keratitis. Ulcerative keratitis is caused, for example, by extended wear of contact lenses.
- peptic ulcer includes both duodenal and gastric ulcers.
- Peptic ulcers are a group of ulcerative disorders of the upper gastrointestinal tract; the primary forms of peptic ulcer are duodenal and gastric ulcer.
- Normally gastric mucosa has the ability to resist the corrosive effects of acid-pepsin. This is a trait which is unique to the gastric mucosa; areas such as the esophagus do not have this ability.
- Injury to the esophageal mucosa occurs from exposure to refluxed gastric juice and ulceration which occurs in the small intestine at the site of surgical attachment to actively secreting gastric mucosa.
- Genito-urinary ulcers treatable with the vitamin D compounds of the invention ⁇ include those caused by, for example, herpes simplex virus as well as other viral, fungal and bacterial infections. See Harrison's Principles of Internal Medicine. E. Braunwald et al . (eds.); McGraw-Hill Book Co., New York, N.Y., 1987, pp. 514-516.
- the vitamin D compounds of the invention may also be administered for the treatment of periodontal disease.
- This disease begins as a marginal inflammation of the gingivae (gingivitis) which slowly spreads to involve the underlying alveolar bone and periodontal ligament.
- the vitamin D compounds may be applied topically, for example, as part of a tooth paste formulation, or may be administered orally or part of a thin film implant between the teeth and gums to give sustained release of the vitamin D compound.
- the film comprises a cellulose polymer. See U.S. Patent No. 4,315,779 to Heyd.
- Y 1 is hydrogen, F, CH 3 , CH 2 CH 3 or X 1 ;
- U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
- Z 1 is F, H or X 1 ;
- R is a double bond or an epoxy group
- X 1 is selected from the group consisting of hydrogen and -OH;
- W is CH-CH3 or 0
- V is CH2 or 0; with the proviso that both W and V are not both 0;
- the compounds of Formula (I) When the compounds of Formula (I) have a double bond at position C-22, they are derivatives of vitamin D2, whereas if the bond at that position is single, and there is a lack of C24 alkyl, they are derivatives of vitamin D3. The latter are preferred.
- vitamins D3 or D2 are vitamins D3 or D2; 1-hydrox vitamins D3 or D2; and 1,25-dihydroxyvitamins D3 or D2, 5,6-epoxy derivatives of vitamin D and its metabolites, 2- ⁇ -(3-hydroxypropoxy)-l alpha,25- dihydroxyvitamin D3, as well as the side chain fluoro derivatives of 1,25-(0H)2 vitamin D and 1-(0H) vitamin D.
- 20- and 22-oxa vitamin D derivatives including 20-oxa-l ⁇ (0H)D, 20-oxa- l ⁇ ,25(0H) 2 D 3 , 22-oxa-l ⁇ (0H)D 3 and 22-oxa-l ⁇ ,25(0H)D 3 as well as pseudo-1-alpha-hydroxyvitamin D derivatives such as dihydrotachysterol and 5,6-trans vitamin D3 and their 25-hydroxy derivatives.
- water soluble derivatives of the aforementioned compounds of Formula (I) obtained by solubilizing such compounds by attaching thetato glycosidic residues such as those disclosed in Holick, U.S. Patent 4,410,515.
- Alternative methods of solubilization are by conjugating compounds of Formula (I) to glycosyl orthoester residues, as disclosed in copending U.S. S.N. 607,117 by Holick et al.. filed May 3, 1984.
- the disclosures of the aforemen tioned patent and application are herein incorporated by reference an made a part hereof.
- Y 2 is hydrogen, fluorine, methyl, ethyl or ORl
- Z 2 is F, H or X 2 ;
- U is hydrogen, -OH or -0-(C 2 -C4 alkyl)-OH;
- R is a double bond or an epoxy group
- X 2 is selected from the group consisting of hydrogen an OR 1 ;
- R 1 is hydrogen or a straight or branched chain glycosidi residue containing 1-20 glycosidic units per residue, or R 1 is a orthoester glycoside moiety of the Formula (III):
- A represents a glucofuranosyl or glucopyranosyl ring
- R 2 is hydrogen, lower alkyl (C1-C4), aralkyl (C7-C10), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C1-C4 alkyl, C1-C4 alkoxy; or naphthyl ;
- R 3 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue;
- W is CH-CH3 or 0
- V is CH2 or 0; with the proviso that both W and V are not both 0;
- the vitamin D compounds are prepared or obtained according to the disclosures of the aforementioned references.
- the 5,6- epoxy derivatives of vitamin D3 are obtained as described in Jpn. Kokai Tokkvo Koho JP 58,216,178 [83,216,178], Dec. 15, 1983.
- the fluoro derivatives are made or obtained as described in Shiina, et al.. Arch. Biochem. Bioohvs 220:90 (1983).
- Methods for preparing the 20- and 22-oxa vitamin D derivatives are disclosed by Abe, J., et al.. Vitamin D Molecular. Cellular and Clinical Endocrinology, p. 310-319, Walter de Gruyter & Co., Berlin (1988).
- the compounds of the invention can be administered in any appropriate pharmaceutically acceptable carrier for oral, parenteral, or topical administration. They can be administered by any means that enhances wound healing, ulcer healing, amelioration of periodontal disease, and inhibition of scar formation in animals, especially humans.
- the dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
- systemic daily dosage of 1,25-dihydroxyvitamin D3 will be from about 0.001 micrograms/kg to 100 micrograms/kg preferably 0.01 to 1.0 micrograms per kg of body weight.
- Dosage forms for topical administration include about 3 to 100 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier.
- the dosage form contains about 5 ⁇ g to 3 mg of 1,25-dihydroxyvitamin D3 per gram of carrier. More preferably, the dosage form contains about 10 to 30 micrograms of 1,25-dihydroxyvitamin D3 per gram of carrier. A most preferred dosage form contains about 15 ug of 1,25-dihydroxyvitamin D3 per gram of carrier.
- the compounds can be employed in dosage forms such as tablets, capsules, powder packets, or liquid solutions, suspensions or elixirs for oral administration, sterile liquid for formulations such as solutions or suspensions for parenteral use.
- a pharmacologically inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as water, glycerol, alcohol, propylene glycol, fatt alcohols, triglycerides, fatty acid esters or mineral oils.
- liquid petroleum isopropylpalirritate, polyethy ⁇ lene glycol ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like.
- Materials such as anti-oxidants, humectants, viscosity stabilizers and the like may be added, if necessary.
- the compounds may also be present as part of a cosmetic formulation which may be formulated according to methods known to those of skill in the art. The compounds can also be administered by means of pumps, tapes or patches.
- Rats were anesthetized with ether. Their backs were prepared by clipping and shaving. Two cutaneous wounds were made on each rat by punching on the right and left sides of the back with a sterile biopsy punch (diameter 4mm, wound thickness: full thickness of skin).
- Control rats received vehicle only on wounds (20 ⁇ l vegetable oil/two wounds/day for 4 days).
- the other four groups of rats (5 rats per group) were used to study the effect of 1,25(0H)2D3 on wound healing at different doses (5 ⁇ g l,25(0H)2D3/g oil, 10 ⁇ g/g oil, 27 ⁇ g/g oil and 54 ⁇ g/g oil 1,25 (0H)2D3). Treatment continued for up to 4 days.
- Wound area was estimated by planimetry. For this purpose, the wound was covered with a transparent plastic film and wound outlines were drawn with a marker. Wound shape was then magnified, was cut out, and weighed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41678189A | 1989-10-04 | 1989-10-04 | |
US416,781 | 1989-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005537A1 true WO1991005537A1 (fr) | 1991-05-02 |
Family
ID=23651271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/005716 WO1991005537A1 (fr) | 1989-10-04 | 1990-10-04 | Procede d'acceleration de la cicatrisation de plaies et d'ulceres, et de traitement de maladie periodontique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0494995A4 (fr) |
JP (1) | JPH05503922A (fr) |
WO (1) | WO1991005537A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014411A1 (fr) * | 1992-12-29 | 1994-07-07 | Holick Michael F | Utilisation de glycosides de vitamine d pour le traitement ou la prevention de l'osteoporose |
EP0862916A4 (fr) * | 1995-11-20 | 2001-01-10 | Kiyoshi Kita | Preparation externe contenant de la vitamine d ou de la vitamine k |
WO2006011849A1 (fr) * | 2004-07-28 | 2006-02-02 | Lipopeptide Ab | Nouvelle utilisation |
EP1748784A4 (fr) * | 2004-05-26 | 2008-02-13 | Cedars Sinai Medical Center | Induction de l'immunite innee par la vitamine d3 et ses analogues |
RU2802822C1 (ru) * | 2022-11-28 | 2023-09-04 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | Средство для местного лечения пародонтита и способ лечения пародонтита |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW422696B (en) | 1995-03-20 | 2001-02-21 | Katsuhiko Mukai | Ophthalmic composition containing active vitamin D |
WO1998053806A1 (fr) * | 1997-05-26 | 1998-12-03 | New Vision Co., Ltd. | Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k |
US6187331B1 (en) | 1997-06-10 | 2001-02-13 | New Vision Co., Ltd. | Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D |
AU2980697A (en) * | 1997-06-10 | 1998-12-30 | New Vision Co., Ltd. | Vitamin d-containing preventives and/or remedies for conjunctival/corneal xerosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655881A (en) * | 1970-01-22 | 1972-04-11 | Commercial Solvents Corp | Method of treating burned skin |
US4410515A (en) * | 1981-04-01 | 1983-10-18 | Massachusetts General Hospital | Vitamin D glycosides and a method of use |
US4521410A (en) * | 1984-05-03 | 1985-06-04 | The General Hospital Corporation | Vitamin D glycosyl orthoesters |
US4610978A (en) * | 1983-03-22 | 1986-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same |
US4728643A (en) * | 1984-11-02 | 1988-03-01 | The General Hospital Corporation | Method of treating psoriasis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622668A (en) * | 1969-08-27 | 1971-11-23 | Joe B Moss | Method of promoting scar-free healing of skin lacerations |
DE2249414A1 (de) * | 1972-10-09 | 1974-04-25 | Georg Dr Rueckheim | Brand- und wundsalbe |
WO1984002845A1 (fr) * | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Onguent pour les soins de la peau contenant des vitamines |
DE3800972A1 (de) * | 1988-01-15 | 1989-07-27 | Asche Karl W | Salbe |
-
1990
- 1990-10-04 EP EP19900916599 patent/EP0494995A4/en not_active Withdrawn
- 1990-10-04 WO PCT/US1990/005716 patent/WO1991005537A1/fr not_active Application Discontinuation
- 1990-10-04 JP JP2515538A patent/JPH05503922A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655881A (en) * | 1970-01-22 | 1972-04-11 | Commercial Solvents Corp | Method of treating burned skin |
US4410515A (en) * | 1981-04-01 | 1983-10-18 | Massachusetts General Hospital | Vitamin D glycosides and a method of use |
US4610978A (en) * | 1983-03-22 | 1986-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same |
US4521410A (en) * | 1984-05-03 | 1985-06-04 | The General Hospital Corporation | Vitamin D glycosyl orthoesters |
US4728643A (en) * | 1984-11-02 | 1988-03-01 | The General Hospital Corporation | Method of treating psoriasis |
Non-Patent Citations (1)
Title |
---|
See also references of EP0494995A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014411A1 (fr) * | 1992-12-29 | 1994-07-07 | Holick Michael F | Utilisation de glycosides de vitamine d pour le traitement ou la prevention de l'osteoporose |
US5508392A (en) * | 1992-12-29 | 1996-04-16 | Holick; Michael F. | Use of vitamin D glycosides, vitamin D orthoester glycosides, vitamin D analog glycosides and vitamin D analog orthoester glycosides for the treatment of osteoporosis |
EP0862916A4 (fr) * | 1995-11-20 | 2001-01-10 | Kiyoshi Kita | Preparation externe contenant de la vitamine d ou de la vitamine k |
EP1748784A4 (fr) * | 2004-05-26 | 2008-02-13 | Cedars Sinai Medical Center | Induction de l'immunite innee par la vitamine d3 et ses analogues |
WO2006011849A1 (fr) * | 2004-07-28 | 2006-02-02 | Lipopeptide Ab | Nouvelle utilisation |
RU2802822C1 (ru) * | 2022-11-28 | 2023-09-04 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | Средство для местного лечения пародонтита и способ лечения пародонтита |
Also Published As
Publication number | Publication date |
---|---|
EP0494995A4 (en) | 1993-03-17 |
EP0494995A1 (fr) | 1992-07-22 |
JPH05503922A (ja) | 1993-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5254538A (en) | Method of treating periodontal disease | |
Kragballe | Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903) | |
US5098899A (en) | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites | |
US4610978A (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
US5324746A (en) | Method of treating damaged mucosal and epithelial tissues with misoprostol | |
Walsh et al. | Calcifying disorders of the skin | |
EP0202276B1 (fr) | Composition pour le traitement du psoriasis | |
EP0766960B1 (fr) | Preparations a usage externe destinees au traitement de dermatoses | |
RU2500387C1 (ru) | Фармацевтическая композиция, содержащая аналог витамина d и смесь сорастворитель - поверхностно-активное вещество | |
Crotty et al. | Ulcerative lichen planus: follow-up of surgical excision and grafting | |
CA2200480C (fr) | Nouvelle utilisation de prostaglandines | |
US5037816A (en) | Method of treating psoriasis | |
US8409628B2 (en) | Methods and compositions for oxygenation of skin to treat skin disorders | |
WO1991005537A1 (fr) | Procede d'acceleration de la cicatrisation de plaies et d'ulceres, et de traitement de maladie periodontique | |
Phillips et al. | Cultured allografts as an adjunct to the medical treatment of problematic leg ulcers | |
MXPA04009288A (es) | Uso de analogos de 19-nor-vitamina d modificados-con-carbono-2 para inducir la formacion de nuevo hueso. | |
Orfanos et al. | Current developments of oral retinoid therapy with three generations of drugs | |
Baadsgaard et al. | Optimal concentration of tacalcitol in once-daily treatment of psoriasis | |
EP0258481B1 (fr) | Compositions pharmaceutiques pour le traitement des maladies de la peau | |
US5994399A (en) | Method of regenerating collagen-containing tissues with misoprostol | |
JP2522962B2 (ja) | 乾癬治療剤 | |
EP0536311A1 (fr) | Compositions comprenant des precurseurs de vitamine d, leurs analogues et leur emploi | |
WO2016138294A1 (fr) | Compositions contenant de l'hespéridine et procédés de traitement de troubles cutanés | |
McDaniel et al. | Sarcoid nodules in Cushing's disease | |
Kragballe | Efficacy and tolerability of calcipotriol in psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990916599 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990916599 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990916599 Country of ref document: EP |